These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35652044)

  • 1. How Sensitive is Sensitivity Analysis?: Evaluation of Pharmacoeconomic Submissions in Korea.
    Bae S; Lee J; Bae EY
    Front Pharmacol; 2022; 13():884769. PubMed ID: 35652044
    [No Abstract]   [Full Text] [Related]  

  • 2. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using economic evaluations to make formulary coverage decisions. So much for guidelines.
    Anis AH; Gagnon Y
    Pharmacoeconomics; 2000 Jul; 18(1):55-62. PubMed ID: 11010604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacoeconomic evaluations submitted for reimbursement in Korea.
    Yim EY; Lim SH; Oh MJ; Park HK; Gong JR; Park SE; Yi SY
    Value Health; 2012; 15(1 Suppl):S104-10. PubMed ID: 22265055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
    Ghabri S; Hamers FF; Josselin JM
    Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of health economic evaluations submitted to the Italian Medicines Agency: current state and future actions.
    Carletto A; Zanuzzi M; Sammarco A; Russo P
    Int J Technol Assess Health Care; 2020 Dec; 36(6):560-568. PubMed ID: 32907656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme.
    Hill SR; Mitchell AS; Henry DA
    JAMA; 2000 Apr; 283(16):2116-21. PubMed ID: 10791503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold.
    Griffiths EA; Hendrich JK; Stoddart SD; Walsh SC
    Clinicoecon Outcomes Res; 2015; 7():463-76. PubMed ID: 26366099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Do Pharmaceutical Companies Model Survival of Cancer Patients? A Review of NICE Single Technology Appraisals in 2017.
    Gallacher D; Auguste P; Connock M
    Int J Technol Assess Health Care; 2019 Jan; 35(2):160-167. PubMed ID: 31017564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.
    Shepherd J; Jones J; Frampton GK; Tanajewski L; Turner D; Price A
    Health Technol Assess; 2008 Jun; 12(28):iii-iv, ix-95. PubMed ID: 18547499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical assessment framework to identify, quantify and interpret the sources of uncertainty in cost-effectiveness analyses.
    Merész G; Dóczy V; Hölgyesi Á; Németh G
    BMC Health Serv Res; 2022 Jun; 22(1):822. PubMed ID: 35752772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of PBAC submissions and outcomes for medicines (2010-2018).
    Lybrand S; Wonder M
    Int J Technol Assess Health Care; 2020 Jun; 36(3):224-231. PubMed ID: 32524923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.